Rejection of an MHC class II negative tumor following induction of murine syngeneic graft-versus-host disease

Bone Marrow Transplantation

Volumn 23, Issue 4, 1999, Pages 363-372

  Bryson, J S ^a,b,d   Jennings, C D ^b   Lowery, D M ^d   Carlson, S L ^c   Pflugh, D L ^d   Caywood, Be ^a   Kaplan, A M ^d  

^a B412 Division of Hematology/Oncology   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

^c UNIVERSITY OF KENTUCKY   (United States)

^d UNIVERSITY OF KENTUCKY MEDICAL CENTER   (United States)

Author keywords

Cyclosporin A; Graft versus host disease; Graft versus tumor; Syngeneic bone marrow transplantation

Indexed keywords

CYCLOSPORIN A; INTERLEUKIN 10; INTERLEUKIN 4; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2;

ANIMAL EXPERIMENT; ARTICLE; B CELL LYMPHOMA; CONTROLLED STUDY; GRAFT VERSUS LEUKEMIA EFFECT; INTRAVENOUS DRUG ADMINISTRATION; LEUKEMIA CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; SURVIVAL; TUMOR IMMUNITY;

EID: 0032966947     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1701557     Document Type: Article

References (52)

1. Armitage JO. Bone marrow transplantation. New Engl J Med 1994; 330: 827-838.
2. Ferrara JML, Deeg HJ. Graft-versus-host disease. New Engl J Med 1991; 324: 667-674.
3. Korngold R, Sprent J. T cell subsets and graft-versus-host disease. Transplantation 1987; 44: 335-339.
4. Kernan NA, Collins NH, Juliano L et al. Clonable T lymphocytes in T cell-depleted bone marrow transplants correlate with development of graft-versus-host disease. Blood 1986; 68: 770-773.
5. Antin JH, Ferrara JLM, Cytokine dysregulation and acute graft-versus-host disease. Blood 1992; 80: 2964-2968.
6. Truitt RL, Atasoylu AA. Impact of pretransplant conditioning and donor T cells on chimerism, graft-versus-host disease, graft-versus-leukemia reactivity, and tolerance after bone marrow transplantation. Blood 1991; 77: 2515-2523.
7. + cells while preserving CD4-and CD8-mediated graft-versus-leukemia effects. Blood 1994; 83: 2560-2569.
8. Sullivan KM, Fefer A, Witherspoon R et al. Graft-versus-leukemia in man: relationship of acute and chronic graft-versus-host disease to relapse of acute leukemia following allogeneic bone marrow transplantation. Prog Clin Biol Res 1987; 244: 391-399.
9. Fefer A, Sullivan KM, Weiden P et al. Graft-versus-leukemia effect in man: the relapse rate of acute leukemia is lower after allogeneic than after syngeneic marrow transplantation. Prog Clin Biol Res 1987; 244: 401-408.
10. Butturini A, Bortin MM, Gale R. Graft-versus-leukemia following bone marrow transplantation. Bone Marrow Transplant 1987; 2: 223-242.
11. Champlin R. T-cell depletion for allogeneic bone marrow transplantation: impact on graft-versus-host disease, engraftment, and graft-versus-leukemia. J Hematother 1993; 2: 27-42.
12. Sosman JA, Oettel K, Smith SD et al. Specific recognition of human leukemic cells by allogeneic T cells: II. Evidence for HLA-D restricted unique determinants on leukemic cells which are cross-reactive with determinants present on unrelated non-leukemic cells. Blood 1990; 75: 2005-2016.
13. Drobyski WR, Piaskowski V, Ash RC et al. Preservation of lymphokine-activated killer cell activity following T cell depletion of human bone marrow. Transplantation 1990; 50: 625-632.
14. Hauch M, Gazzola MV, Small T et al. Anti-leukemia potential activity of interleukin-2 activated natural killer cells after bone marrow transplantation for chronic myelogenous leukemia. Blood 1990; 75: 2250-2262.
15. Glazier A, Tutschka PJ, Farmer ER, Santos GW. Graft-versus-host disease in cyclosporin A-treated rats after syngeneic and autologous bone marrow transplantation. J Exp Med 1983; 158: 1-8.
16. Cheney RT, Sprent J. Capacity of cyclosporine to induce autograft-versus-host disease and impair intrathymic T cell differentiation. Transplant Proc 1985; 17: 528-530.
17. Bryson JS, Jennings CD, Caywood BE, Kaplan A. Induction of a syngeneic graft-versus-host disease-like syndrome in DBA/2 mice. Transplantation 1989; 48: 1042-1047.
18. Jones RJ, Hess AD, Mann RB et al. Induction of graft-versus-host disease after autologous bone marrow transplantation. Lancet 1989; 1: 754-757.
19. Talbot DC, Powles R, Sloane JP et al. Cyclosporine-induced graft-versus-host disease following autologous bone marrow transplantation in acute myeloid leukemia. Bone Marrow Transplant 1990; 6: 17-20.
20. Carella AM, Gaozza E, Congiu A et al. Cyclosporine-induced graft-versus-host disease after autologous bone marrow transplantation in hematological malignancies. Ann Hematol 1991; 62: 156-159.
21. Yeager AM, Vogelsang GB, Jones RJ et al. Induction of cutaneous graft-versus-host disease by administration of cyclosporine to patients undergoing autologous bone marrow transplantation for acute myeloid leukemia. Blood 1992; 79: 3031-3035.
22. Kennedy MJ, Vogelsang GB, Beveridge RA et al. Phase I trial of intravenous cyclosporine to induce graft-versus-host disease in women undergoing autologous bone marrow transplantation for breast cancer. J Clin Oncol 1993; 11: 478-484.
23. Kennedy MJ, Vogelsang GB, Jones RJ et al. Phase I trial of intravenous interferon gamma to potentiate cyclosporine-induced graft-versus-host disease in women undergoing autologous bone marrow transplantation for breast cancer. J Clin Oncol 1994; 12: 249-257.
24. Hess AD, Bright EC, Thoburn C et al. Specificity of effector T lymphocytes in autologous graft-versus-host disease: role of the major histocompatibility complex class II invariant chain peptide. Blood 1997; 89: 2203-2209.
25. Noga SJ, Horwitz L, Kim H et al. Interferon-γ potentiates the antitumor effect of cyclosporine-induced autoimmunity. J Hematother 1992; 1: 75-84.
26. Hess AD, Horwitz L, Beschorner WE, Santos GW. Development of a graft-versus-host disease-like syndrome in cyclosporine-treated rats after syngeneic bone marrow transplantation: I. Development of cytotoxic T lymphocytes with apparent polyclonal anti-Ia-specificity, including autoreactivity. J Exp Med 1985; 161: 718-730.
27. Bryson JS, Jennings CD, Caywood BE, Kaplan AM. Strain specificity in the induction of syngeneic graft-versus-host disease in mice. Transplantation 1990; 51: 911-913.
28. + bone marrow cells regulate the induction of murine syngeneic graft-versus-host disease. Transplantation 1993; 56: 941-945.
29. Bergman Y, Haimovich J. Characterization of a carcinogen-induced murine B lymphocyte cell line of C3H/eB origin. Eur J Immunol 1977; 7: 413-417.
30. Chang CH, Fontes JD, Peterlin M, Flavell RA. Class II transactivator (CIITA) is sufficient for the inducible expression of major histocompatibility complex class II genes. J Exp Med 1994; 180: 1367-1374.
31. Bucy RP, Xu XY, Li J, Huang GQ. Cyclosporin A-induced autoimmune disease in mice. J Immunol 1993; 151: 1039-1051.
32. Noelle R, Krammer PH, Ohara J et al. Increased expression of Ia antigens on resting B cells: an additional role for B cell growth factor. Proc Natl Acad Sci USA 1984; 81: 6149-6153.
33. Noelle RJ, Kuziel WA, Maliszewski CR et al. Regulation of the expression of multiple class II genes in murine B cells by B cell stimulatory factor-1 (BSF-1). J Immunol 1986; 137: 1718-1723.
34. Go NF, Castle BE, Barren R et al. Interleukin 10, a novel B cell stimulatory factor: unresponsiveness of X chromosome-linked immunodeficiency B cells. J Exp Med 1990; 172: 1625-1631.
35. King DP, Jones PP. Induction of Ia and H-2 antigens on a macrophage cell line by immune interferon. J Immunol 1983; 131: 315-318.
36. Steimle V, Otten LA, Zufferey M, Mach B. Complementation cloning of an MHC class II transactivator mutated in hereditary MHC class II deficiency (or bare lymphocyte syndrome). Cell 1993; 75: 135-146.
37. Reith W, Steimle V, Mach B. Molecular defects in the bare lymphocyte syndrome and the regulation of MHC class II genes. Immunol Today 1995; 16: 539-546.
38. Mach B, Steimle V, Martinez-Soria E, Reith W. Regulation of MHC class II genes: lessons from disease. Ann Rev Immunol 1996; 14: 301-333.
39. Ramassar V, Goes N, Hobart M, Halloran PF. Evidence for the in vivo role of class II transactivator in basal and IFN-γ induced class II expression in mouse tissue. Transplantation 1996; 62: 1901-1907.
40. Charak BS, Agah R, Mazumder A. Synergism of interleukin-2 and cyclosporin A in induction of a graft-versus-leukemia effect without graft-versus-host disease after syngeneic bone marrow transplantation. Blood 1992; 80: 1-6.
41. Hashino S, Imamura M, Tanaka J et al. Antitumor effect in cyclosporin A-or FK506-treated mice after syngeneic bone marrow transplantation. Leuk Lymphoma 1996; 21: 331-337.
42. Singhal S, Vourka-Katussis U, Mehta J et al. Failure of cyclosporine to induce graft-versus-host disease or graft-versus-leukemia after syngeneic bone marrow transplantation in mice. Leukemia Res 1996; 20: 941-946.
43. Bryson JS, Lake-Bullock H, Pflugh DL et al. In vivo reactivity of T cell clones isolated from mice with syngeneic graft-versus-host disease. Transplantation 1995; 60: 171-178.
44. Kosugi A, Shearer GM. Effect of cyclosporin A on lymphopoiesis. III. Augmentation of the generation of natural killer cells in bone marrow transplanted mice treated with cyclosporin A. J Immunol 1991; 146: 1416-1421.
45. Hanna N, Fidler IJ. Relationship between metastatic potential and resistance to natural killer cell mediated cytoxicity in three murine tumor systems. J Natl Cancer Inst 1981; 66: 1183-1188.
46. Fidler IJ, Shroit AJ. Recognition and destruction of neoplastic cells by activated macrophages: discrimination of altered self. Biochem Biophys Acta 1988; 948: 151-173.
47. Kobayashi M, Fitz L, Ryan M et al. Indentification and purification of natural killer cell stimulatory factor (NKSF) a cytokine with multiple biologic effects on human lymphocytes. J Exp Med 1989; 170: 827-845.
48. Hsieh C-S, Mactonia SE, Tripp CS et al. Development of ThI CD4 T cells through IL-12 produced by Listeria-induced macrophages. Science 1993; 260: 547-549.
49. Schoenhaut DS, Chua AO, Wolitsky AG et al. Cloning and expression of murine IL-12. J Immunol 1992; 148: 3433-3340.
50. Tripp CS, Wolf SF, Unanue ER. Interleukin-12 and tumor necrosis factor a are costimulators of Interferon γ production by natural killer cells in severe combined immunodeficiency mice with listeriosis, and interleukin 10 is a physiologic antagonist. Proc Natl Acad Sci USA 1993; 90: 3725-3729.
51. Sieling PA, Wang X-H, Gately MK et al. IL-12 regulates T helper type 1 cytokine responses in human infectious disease. J Immunol 1994; 152: 3639-3647.
52. Brunda MJ, Luistro L, Hendrzak JA et al. Role of interferon-γ in mediating the antitumor efficacy of interleukin-12. J Immunother 1995; 17: 71-77.